By Deena Beasley Dec 12 (Reuters) - Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite ...
Modified Kisunla dosing cut ARIA-E risk by 41% at 24 weeks and 35% at 52 weeks. Amyloid plaque reduction remained similar: 67% (modified) vs. 69% (original) at 24 weeks. Get a Year of Fast, Actionable ...
Only therapy with evidence to support completing course of treatment once amyloid plaques are reduced to minimal levels INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (LLY) ...
INDIANAPOLIS — A European regulatory committee rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially dangerous risks of brain bleeding and swelling. The European Medicines ...
Kisunla was first approved in the United States in July 2024, approved in Japan in September 2024 and then in Great Britain in October 2024 "Bringing Alzheimer's disease treatment options to the ...
Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having completed treatment Data underscores the ...
INDIANAPOLIS, Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback